Bremen, May 27, 2021 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, today announced its results for the first half of fiscal year 2020/2021, reporting period October 1, 2020 to March 31, 2021.
Revenues generated in the first half of the year amounted to € 8,080 k, approximately 7 % below the previous year's level (prev. year: € 8,677 k). The sale of licenses accounted for 30 % (prev. year: 31 %) of revenues, maintenance revenues for 35 % (prev. year: 40 %), and other revenues for 35 % (prev. year: 29 %), which include services for and recharges to affiliated companies and the parent company.
Earnings before interest and taxes (EBIT) fell from € 2,937 k to € 2,378 k, which corresponds to an EBIT margin of 36 %, mainly as a result of lower sales, higher personnel expenses and higher other operating expenses compared with the previous year.
Income from loans of financial assets amounted to € 80 k (prev. year: € 90 k) and was attributable to interest income from the loan granted to Varex Imaging Deutschland AG. This resulted in earnings before taxes (EBT) of € 2,458 k (prev. year: € 3,022 k).
In the past half-year, income taxes of € 42 k (prev. year: € 42 k) were incurred. Therefore, taking into account the expense from the profit to be transferred to Varex Imaging Deutschland AG of € 2,416 k (prev. year: € 2,980 k), the net profit for the year amounted to € 0 k (prev. year: € 0 k).
"Looking at the figures, the first half of the year was a successful six months for MeVis, despite the expected decline in revenues and EBIT," said Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. "Although license sales and maintenance sales are down slightly, other sales, in particular development services, have developed somewhat better than expected in the last six months. Mainly, we are benefiting here from collaborative projects with Varian Medical Systems and Varex Imaging Corporation. Even more than a year after the start of the Corona pandemic, we are still in an exceptional situation. Although the daily work routine has changed considerably, the Corona pandemic has not yet had a major negative impact on our sales development. For this reason, we are maintaining our forecast at this time: for fiscal 2020/2021, a significant decline in sales compared with the previous year to between € 15.0 million and € 15.5 million is expected. In addition to the renewed expected decline in sales with the customer Hologic, falling sales revenues are expected in the area of development services, as fewer development services will be provided compared with 2019/2020. Earnings before interest and taxes (EBIT) are expected to decline to between € 3.5 million and € 4.0 million. The forecast decline in sales, with earnings from exchange rate differences expected to break even, is the main driver of the EBIT decrease."